TWIICE

TWIICE operates at the intersection of medical devices, rehabilitation robotics and mobility assistance. Its focus is wearable lower-limb exoskeletons for people with mobility impairments, rather than general-purpose industrial robotics. TWIICE One is described as supporting standing, walking and stair climbing; WIITE adapts the underlying exoskeleton concept for ski touring. The company also emphasizes adapting devices to different body types, conditions and user needs, suggesting a user-specific approach rather than a single-use industrial platform. Its stated work spans robotics, ergonomics, human-machine interfaces and gait training. Broadly, TWIICE’s differentiating signals are the combination of rehabilitation use cases with outdoor mobility applications, including uneven terrain and ski touring, and its record of participation in four consecutive Cybathlon competitions, with a second-place result in 2020. Its small reported employee range and grant-led funding history indicate a focused operation, not evidence of scale relative to larger medical-device developers.

Founded in 2016, TWIICE has developed from an early-stage mobility-technology venture into a small company with two described products: TWIICE One for walking assistance and WIITE for ski touring. Its disclosed financing is grant- and assistance-led rather than equity-round-led. The company’s four recorded funding rounds include a $102,770 grant dated Nov 6, 2016, a $10,079 grant dated Mar 28, 2017 and non-equity assistance dated May 23, 2017; a further grant from Innosuisse was announced on Sep 1, 2025, without a disclosed amount. The 2025 grant is a notable later funding milestone after several years without a dated round in the listed history. Product and visibility milestones include a 2018 feature on TWIICE One, a 2021 item about ski touring and second place at the 2020 Cybathlon. A 2024 FIT Boost article and 2025 technology-project coverage point to continued development activity, but do not by themselves confirm commercialization, regulatory clearance or expanded production. The reported employee band is 1–10, and the available hiring information mentions a careers page without specific roles. Overall, the record suggests gradual, grant-supported product development; evidence on revenue, headcount growth and deployment scale is limited.